FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1988553216> ?p ?o ?g. }

• W1988553216 endingPage "S372" @default.
• W1988553216 startingPage "S372" @default.
• W1988553216 abstract "Background: While emotional symptoms such as depressed mood and loss of interest have traditionally been considered to constitute the core symptoms of major depressive disorder (MDD), the prevalence and importance of painful physical symptoms such as back pain, abdominal pain, and musculoskeletal pain is becoming increasingly appreciated. Antidepressants possessing dual serotonin/norepinephrine (5-HT/NE) reuptake inhibition may demonstrate greater efficacy in the alleviation of pain. The efficacy of duloxetine, a balanced and potent dual reuptake inhibitor of 5-HT and NE, was evaluated within a cohort of depressed patients with associated painful physical symptoms.Methods: In this multicenter, double-blind, placebo-controlled study, patients meeting DSM-IV criteria for MDD were randomized to receive placebo (N=141) or duloxetine 60 mg QD (N=141). Patients were required to have a 17-item Hamilton Rating Scale for Depression (HAMD17) total score ⩾15, a Clinical Global Impression of Severity (CGI-S) score ⩾4, and a Brief Pain Inventory (BPI) Average Pain score ⩾2 at baseline. The primary efficacy measure was the BPI Average Pain score, while secondary measures included other BPI items, the HAMD17 total score, CGI-S, the Patient Global Impression of Improvement (PGI-I) scale, Visual Analog Scales (VAS) for pain, and the Symptom Questionnaire, Somatic Subscale (SQSS). Safety was evaluated by recording treatment-emergent adverse events (spontaneously reported), vital signs, and laboratory analytes.Results: Mean changes in BPI Average Pain for duloxetine- and placebo-treated patients differed significantly at most visits, but only approached significance at endpoint (p=0.066). For the main effect of treatment (pooling all visits), significant advantages for duloxetine-treated patients were found in 10 of 11 assessed BPI pain severity and pain interference items, in addition to VAS overall pain and back pain. Mean changes in pain measures for duloxetine-treated patients corresponded to improvements of 25–50%, compared with 19–39% for placebo. Mean changes at endpoint in depression rating scales (HAMD17, CGI-S, PGI-I) did not differ significantly between duloxetine and placebo treatment groups due to unusually high placebo response. The magnitude of placebo treatment effects (as measured by HAMD17 total score and Maier subscale) was significantly smaller in patients with ⩾1 previous depressive episode, compared to those patients with no previous episodes. In patients with ⩾1 previous depressive episode the advantage of duloxetine over placebo was similar to previous studies. Rates of discontinuation due to adverse events were 14.2% vs. 2.1% for duloxetine and placebo, respectively (p<0.001). Treatment-emergent adverse events reported at a significantly higher rate by duloxetine-treated patients included nausea, dry mouth, fatigue, and decreased appetite.Conclusions: In this study, duloxetine (60 mg QD) was shown to be an effective treatment for the painful physical symptoms which are frequently associated with depression. Improvements in pain severity occurred independently of changes in depressive symptom severity." @default.
• W1988553216 created "2016-06-24" @default.
• W1988553216 creator A5010035939 @default.
• W1988553216 creator A5011761022 @default.
• W1988553216 creator A5013813636 @default.
• W1988553216 creator A5031345514 @default.
• W1988553216 creator A5040965464 @default.
• W1988553216 creator A5054609820 @default.
• W1988553216 creator A5061724175 @default.
• W1988553216 creator A5069512292 @default.
• W1988553216 creator A5083145819 @default.
• W1988553216 creator A5088588601 @default.
• W1988553216 date "2010-08-01" @default.
• W1988553216 modified "2023-09-26" @default.
• W1988553216 title "P.2.c.008 Assessment of tolerability and efficacy of duloxetine in the treatment of depressed patients with Parkinson's disease" @default.
• W1988553216 doi "https://doi.org/10.1016/s0924-977x(10)70523-x" @default.
• W1988553216 hasPublicationYear "2010" @default.
• W1988553216 type Work @default.
• W1988553216 sameAs 1988553216 @default.
• W1988553216 citedByCount "0" @default.
• W1988553216 crossrefType "journal-article" @default.
• W1988553216 hasAuthorship W1988553216A5010035939 @default.
• W1988553216 hasAuthorship W1988553216A5011761022 @default.
• W1988553216 hasAuthorship W1988553216A5013813636 @default.
• W1988553216 hasAuthorship W1988553216A5031345514 @default.
• W1988553216 hasAuthorship W1988553216A5040965464 @default.
• W1988553216 hasAuthorship W1988553216A5054609820 @default.
• W1988553216 hasAuthorship W1988553216A5061724175 @default.
• W1988553216 hasAuthorship W1988553216A5069512292 @default.
• W1988553216 hasAuthorship W1988553216A5083145819 @default.
• W1988553216 hasAuthorship W1988553216A5088588601 @default.
• W1988553216 hasConcept C118552586 @default.
• W1988553216 hasConcept C126322002 @default.
• W1988553216 hasConcept C14184104 @default.
• W1988553216 hasConcept C142724271 @default.
• W1988553216 hasConcept C15744967 @default.
• W1988553216 hasConcept C168563851 @default.
• W1988553216 hasConcept C1862650 @default.
• W1988553216 hasConcept C197934379 @default.
• W1988553216 hasConcept C203092338 @default.
• W1988553216 hasConcept C204787440 @default.
• W1988553216 hasConcept C27081682 @default.
• W1988553216 hasConcept C2776000289 @default.
• W1988553216 hasConcept C2778375690 @default.
• W1988553216 hasConcept C2779177272 @default.
• W1988553216 hasConcept C2780051608 @default.
• W1988553216 hasConcept C2780052408 @default.
• W1988553216 hasConcept C2780733359 @default.
• W1988553216 hasConcept C2780764818 @default.
• W1988553216 hasConcept C2781118164 @default.
• W1988553216 hasConcept C2910564767 @default.
• W1988553216 hasConcept C31487548 @default.
• W1988553216 hasConcept C558461103 @default.
• W1988553216 hasConcept C71924100 @default.
• W1988553216 hasConceptScore W1988553216C118552586 @default.
• W1988553216 hasConceptScore W1988553216C126322002 @default.
• W1988553216 hasConceptScore W1988553216C14184104 @default.
• W1988553216 hasConceptScore W1988553216C142724271 @default.
• W1988553216 hasConceptScore W1988553216C15744967 @default.
• W1988553216 hasConceptScore W1988553216C168563851 @default.
• W1988553216 hasConceptScore W1988553216C1862650 @default.
• W1988553216 hasConceptScore W1988553216C197934379 @default.
• W1988553216 hasConceptScore W1988553216C203092338 @default.
• W1988553216 hasConceptScore W1988553216C204787440 @default.
• W1988553216 hasConceptScore W1988553216C27081682 @default.
• W1988553216 hasConceptScore W1988553216C2776000289 @default.
• W1988553216 hasConceptScore W1988553216C2778375690 @default.
• W1988553216 hasConceptScore W1988553216C2779177272 @default.
• W1988553216 hasConceptScore W1988553216C2780051608 @default.
• W1988553216 hasConceptScore W1988553216C2780052408 @default.
• W1988553216 hasConceptScore W1988553216C2780733359 @default.
• W1988553216 hasConceptScore W1988553216C2780764818 @default.
• W1988553216 hasConceptScore W1988553216C2781118164 @default.
• W1988553216 hasConceptScore W1988553216C2910564767 @default.
• W1988553216 hasConceptScore W1988553216C31487548 @default.
• W1988553216 hasConceptScore W1988553216C558461103 @default.
• W1988553216 hasConceptScore W1988553216C71924100 @default.
• W1988553216 hasLocation W19885532161 @default.
• W1988553216 hasOpenAccess W1988553216 @default.
• W1988553216 hasPrimaryLocation W19885532161 @default.
• W1988553216 hasRelatedWork W1593963136 @default.
• W1988553216 hasRelatedWork W1971489430 @default.
• W1988553216 hasRelatedWork W1971663696 @default.
• W1988553216 hasRelatedWork W1973239436 @default.
• W1988553216 hasRelatedWork W1981808732 @default.
• W1988553216 hasRelatedWork W1982721912 @default.
• W1988553216 hasRelatedWork W1990079987 @default.
• W1988553216 hasRelatedWork W2013125957 @default.
• W1988553216 hasRelatedWork W2084168719 @default.
• W1988553216 hasRelatedWork W2113214053 @default.
• W1988553216 hasVolume "20" @default.
• W1988553216 isParatext "false" @default.
• W1988553216 isRetracted "false" @default.
• W1988553216 magId "1988553216" @default.
• W1988553216 workType "article" @default.